Oramed Pharmaceuticals 過去の業績
過去 基準チェック /26
Oramed Pharmaceuticals has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 12.7% per year.
主要情報
6.8%
収益成長率
20.5%
EPS成長率
Pharmaceuticals 業界の成長 | 6.0% |
収益成長率 | -12.7% |
株主資本利益率 | 11.8% |
ネット・マージン | n/a |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06収支内訳
Oramed Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 0 | 21 | 8 | 5 |
31 Mar 24 | 1 | 10 | 8 | 6 |
31 Dec 23 | 1 | 6 | 8 | 9 |
30 Sep 23 | 2 | -16 | 9 | 14 |
30 Jun 23 | 3 | -20 | 11 | 19 |
31 Mar 23 | 3 | -30 | 11 | 26 |
31 Dec 22 | 3 | -37 | 16 | 28 |
30 Sep 22 | 3 | -46 | 20 | 32 |
30 Jun 22 | 3 | -46 | 19 | 33 |
31 Mar 22 | 3 | -40 | 18 | 27 |
31 Dec 21 | 3 | -35 | 13 | 27 |
30 Nov 21 | 3 | -25 | 8 | 22 |
31 Aug 21 | 3 | -22 | 6 | 21 |
31 May 21 | 3 | -18 | 4 | 18 |
28 Feb 21 | 3 | -15 | 4 | 15 |
31 Dec 20 | 3 | -22 | 5 | 21 |
30 Nov 20 | 3 | -15 | 4 | 14 |
31 Aug 20 | 3 | -12 | 4 | 10 |
31 May 20 | 3 | -11 | 4 | 9 |
29 Feb 20 | 3 | -13 | 4 | 11 |
30 Nov 19 | 3 | -13 | 4 | 11 |
31 Aug 19 | 3 | -14 | 4 | 14 |
31 May 19 | 3 | -15 | 4 | 14 |
28 Feb 19 | 3 | -15 | 4 | 14 |
30 Nov 18 | 3 | -14 | 4 | 14 |
31 Aug 18 | 2 | -13 | 4 | 12 |
31 May 18 | 2 | -12 | 4 | 12 |
28 Feb 18 | 2 | -10 | 3 | 10 |
30 Nov 17 | 2 | -10 | 3 | 10 |
31 Aug 17 | 2 | -10 | 3 | 10 |
31 May 17 | 2 | -13 | 2 | 11 |
28 Feb 17 | 2 | -13 | 2 | 10 |
30 Nov 16 | 1 | -11 | 2 | 8 |
31 Aug 16 | 1 | -11 | 2 | 8 |
31 May 16 | 0 | -8 | 3 | 6 |
29 Feb 16 | 0 | -8 | 3 | 6 |
30 Nov 15 | 0 | -8 | 3 | 5 |
31 Aug 15 | 0 | -7 | 3 | 5 |
31 May 15 | 0 | -7 | 3 | 4 |
28 Feb 15 | 0 | -7 | 3 | 4 |
30 Nov 14 | 0 | -6 | 3 | 4 |
31 Aug 14 | 0 | -6 | 3 | 3 |
31 May 14 | 0 | -5 | 2 | 3 |
28 Feb 14 | 0 | -4 | 2 | 3 |
質の高い収益: ORMP has a high level of non-cash earnings.
利益率の向上: ORMP became profitable in the past.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ORMP has become profitable over the past 5 years, growing earnings by 6.8% per year.
成長の加速: ORMP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
収益対業界: ORMP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
株主資本利益率
高いROE: ORMP's Return on Equity (11.8%) is considered low.